Hepatitis A–E: Comparison, HBV Serology & HCV Treatment

Compare hepatitis A–E for USMLE: genome, envelope, transmission, chronicity. Master HBV serology, HCV treatment, and HEV severity in pregnancy.

Why Hepatitis Viruses Matter for Step Exams

Viral hepatitis is a classic high-yield topic for **USMLE Step 1** and **USMLE Step 2 CK**. Questions frequently test:

• Comparing **hepatitis A–E (HAV, HBV, HCV, HDV, HEV)** by genome type, envelope, and transmission
• Knowing **which viruses become chronic** and which are strictly acute
• Interpreting **HBV serology patterns** to determine stage and infectivity
• Recognizing **HCV diagnosis and treatment with direct-acting antivirals (DAAs)**
• Identifying key clinical clues such as **HEV in pregnancy** and **HAV outbreaks and prevention**

Mastering these patterns lets you quickly identify the likely virus in a vignette, choose appropriate diagnostic tests, and pick the correct management strategy.

---

Pathophysiology and Virology: Comparing Hepatitis A–E

Viral hepatitis refers to liver inflammation caused by **five main hepatotropic viruses**:

• **HAV (Hepatitis A virus)**
• **HBV (Hepatitis B virus)**
• **HCV (Hepatitis C virus)**
• **HDV (Hepatitis D virus)**
• **HEV (Hepatitis E virus)**

Each virus differs in **genome type, envelope, transmission, and chronicity**. These core features are heavily tested on USMLE Step 1 and form the foundation for clinical reasoning on Step 2 CK.

High-Yield Comparison of Hepatitis Viruses

| Virus | Genome / Envelope | Transmission | Chronic Infection? | Key Features | |-------|-------------------|--------------|--------------------|--------------| | **HAV** | RNA, **non-enveloped** (Picornavirus) | **Fecal–oral** (contaminated food/water) | **No** | Acute, self-limited; outbreaks in daycare, travelers; post-exposure prophylaxis available | | **HBV** | **DNA**, enveloped (Hepadnavirus) | **Blood, sexual, perinatal** | **Yes** (5–10% adults) | Vaccine-preventable; serologic markers guide stage and infectivity | | **HCV** | RNA, enveloped (Flavivirus) | **Blood** (IVDU, transfusion pre-1992) | **Yes** (~80%) | Antigenic variability → no vaccine; curable with direct-acting antivirals | | **HDV** | RNA, **defective** (requires HBV) | Blood, sexual, perinatal (via **HBsAg**) | **Yes** | Coinfection or superinfection; superinfection more severe | | **HEV** | RNA, **non-enveloped** (Hepevirus) | **Fecal–oral** (waterborne) | **No** (except in immunocompromised) | Fulminant hepatitis in pregnancy; common in Asia, Africa |

**Step 1 focus:**

• Memorize **DNA vs RNA**, **enveloped vs non-enveloped**, and **transmission route**.
• Correlate with **pathogenesis and chronicity**:
• **Acute only**: HAV, HEV (except chronic in some immunocompromised patients)
• **Can be chronic**: HBV, HCV, HDV

**Step 2 CK focus:**

• Use these features to identify the **likely virus** in a vignette.
• Decide on **vaccination, antiviral therapy, or supportive care**.
• Recognize **HEV in pregnancy** as a high-mortality scenario needing urgent supportive management.

---

Clinical Presentation of Each Hepatitis Virus

Across all hepatitis viruses, typical acute hepatitis symptoms include:

• Fatigue, malaise
• Jaundice
• Dark urine
• Elevated **ALT/AST**

The **course and complications**, however, differ by virus.

Hepatitis A Virus (HAV)

• **Non-enveloped RNA virus**
• **Fecal–oral transmission** via contaminated food and water
• **Acute, self-limited** hepatitis with **no chronic sequelae**

**Key clinical features:**

• **Incubation:** ~4 weeks
• **Symptoms:** fatigue, jaundice, dark urine, elevated ALT/AST
• **Epidemiology:** outbreaks in **daycare** settings and **travelers** to areas with poor sanitation

**Step 1 pearl:** HAV is **non-enveloped**, which explains its **environmental stability** and survival in the GI tract. There is **no carrier state** and **no association with hepatocellular carcinoma (HCC)**.

Hepatitis B Virus (HBV)

• **Partially double-stranded DNA virus**
• Transmitted via **blood, sexual contact, perinatal exposure**
• Can cause **acute and chronic hepatitis**, **cirrhosis**, and **HCC**

**Chronic infection risk:**

• Adults: ~**5%**
• Neonates: ~**90%**

**Extrahepatic manifestations:**

• **Polyarteritis nodosa**
• **Membranous glomerulonephritis**

HBV uses **reverse transcriptase** during replication **despite being a DNA virus**, a classic Step 1 detail.

Hepatitis C Virus (HCV)

• **Enveloped RNA virus**
• Transmitted primarily via **blood exposure**:
• Intravenous drug use (IVDU)
• Transfusions **before 1992**
• Hemodialysis
• Needle-stick injuries

**Chronic infection:** develops in **most cases (~80%)**, with progression to **cirrhosis** and **HCC**.

**Extrahepatic manifestations:**

• **Mixed cryoglobulinemia**
• **Membranoproliferative glomerulonephritis**
• **Porphyria cutanea tarda**

**Pathogenesis note (Step 1):**

• HCV has **extensive antigenic variation** in its envelope glycoproteins → **no effective vaccine**.
• **Chronic inflammation is largely immune-mediated**, not directly cytopathic.

Hepatitis D Virus (HDV)

• **Defective RNA virus** that **requires HBV (HBsAg)** for replication and transmission
• Occurs as:
• **Coinfection**: simultaneous HBV + HDV
• **Superinfection**: HDV infects a patient with **chronic HBV**

**Clinical course:**

• **Coinfection**: usually **self-limited**
• **Superinfection**: often **more severe**, can **accelerate cirrhosis**

Hepatitis E Virus (HEV)

• **Non-enveloped RNA virus**
• **Fecal–oral transmission**, often via contaminated water in **endemic regions** (Asia, Africa)

**Clinical course:**

• Usually **self-limited acute hepatitis**
• Can become **chronic in immunocompromised hosts**
• **High mortality in pregnant women** due to **fulminant hepatic failure**

HEV is **non-enveloped but unstable in chlorinated water**, contributing to **outbreaks after heavy rains or floods**.

---

Diagnostic Approach: Labs, Serology, and Imaging

On USMLE Step 1 and Step 2 CK, you must recognize **which tests confirm infection** and how to **interpret HBV serology**.

HAV Diagnosis

• **Anti-HAV IgM**: indicates **acute infection**
• **Anti-HAV IgG**: indicates **immunity** (past infection or vaccination)

HBV Serology: Core for Step Exams

HBV serologic markers determine **infection stage, infectivity, and immunity**.

| Marker | Meaning | |--------|---------| | **HBsAg** | Active infection (**acute or chronic**) | | **Anti-HBs** | Recovery or **immunity** (including from vaccine) | | **HBeAg** | **High infectivity** | | **Anti-HBe** | **Low infectivity** | | **Anti-HBc IgM** | **Acute infection**; hallmark of the **"window period"** | | **Anti-HBc IgG** | **Chronic or past infection** |

**High-yield concept: the window period**

• During the **window period**, **HBsAg has disappeared** and **anti-HBs is not yet detectable**.
• The **only positive marker** may be **anti-HBc IgM**.

**Vaccination pattern:**

• **Isolated anti-HBs positivity** (no anti-HBc) = **immunity from vaccination**.

HCV Diagnosis

• **HCV RNA**: confirms **active infection**
• **Anti-HCV**: indicates **exposure**, but not necessarily active viremia

On Step 2 CK, when chronic HCV is suspected, you should **order HCV RNA** to confirm active infection and guide treatment.

HDV Diagnosis (Conceptual)

While specific tests are not detailed in the source, the key exam concept is **clinical suspicion**:

• In a patient with **chronic HBV** who **acutely worsens**, suspect **HDV superinfection**.

HEV Diagnosis

• **Anti-HEV IgM** or **HEV RNA**: used to confirm infection

This is particularly important in **pregnant women** from **endemic regions** with acute hepatitis.

Imaging and Surveillance

For **chronic HCV** with cirrhosis, Step 2 CK emphasizes:

• **HCC screening** with **ultrasound and AFP every 6 months**

Chronic HBV also requires **monitoring for HCC and cirrhosis**, though specific imaging intervals are not detailed in the source.

---

Management and Prevention Strategies

HAV: Prevention and Post-Exposure Prophylaxis

**Prevention:**

• **Inactivated HAV vaccine**
• **Improved hygiene and sanitation**

**Post-exposure prophylaxis:**

• **Immune globulin** can be given after exposure.

**Step 2 CK focus:**

• In outbreak scenarios (e.g., **restaurant exposure**), recognize the need for **public health notification**.
• Offer **post-exposure prophylaxis** with **vaccine or immune globulin** depending on risk and timing.

HBV: Vaccination, Perinatal Management, and Chronic Care

**Prevention:**

• **HBV vaccine** → produces **anti-HBs** (immunity)
• Vaccination also **prevents HDV infection**, since HDV requires **HBsAg**.

**Perinatal management:**

• For **pregnant women with high viral load**:
• Initiate **antiviral therapy in the third trimester**.
• At birth, give neonates **both HBV vaccine and HBIG** (hepatitis B immune globulin).

**Chronic HBV management:**

• Monitor for **cirrhosis** and **HCC**.
• Suppress HBV replication (specific drugs not detailed in the source) and evaluate for **transplant** in end-stage disease.

HCV: Curative Therapy with Direct-Acting Antivirals

**Treatment:**

• **Direct-acting antivirals (DAAs)** achieve **>95% cure**.

**Step 2 CK focus:**

• Recognize **chronic HCV** as a cause of **cirrhosis** and **HCC**.
• Order **HCV RNA** to confirm **active infection** before starting DAAs.
• In cirrhotic patients, **screen for HCC** with **ultrasound and AFP every 6 months**.

HDV: Prevention via HBV Control

• No specific HDV antiviral is described in the source.
• **Prevention** is through **HBV vaccination** (prevents HDV by eliminating HBsAg).

**Management focus:**

• In **HDV superinfection**, disease is often **severe** and may **accelerate cirrhosis**.
• Emphasize **HBV suppression** and **transplant evaluation** for end-stage disease.

HEV: Supportive Care and Water Safety

**Management:**

• Treatment is **supportive**.

**Prevention:**

• **Improved sanitation** and **clean water supply**
• A **vaccine is available in some countries** (not universal)

**Step 2 CK focus:**

• In a **pregnant woman** from an **endemic region** with acute hepatitis, suspect **HEV**.
• Recognize **high mortality risk** due to **fulminant hepatic failure**.

---

High-Yield Differentials and Common Pitfalls

USMLE questions often require distinguishing between hepatitis viruses based on **transmission, chronicity, and special associations**.

Differentiating the Hepatitis Viruses

| Scenario / Clue | Most Likely Virus | Reason | |-----------------|-------------------|--------| | **Daycare outbreak**, contaminated food, acute self-limited hepatitis | **HAV** | Fecal–oral, non-enveloped, no chronicity | | **Traveler** to area with poor sanitation, acute hepatitis | **HAV or HEV** | Both fecal–oral; HEV especially if from Asia/Africa | | **Pregnant woman** with acute hepatitis and high mortality risk | **HEV** | Fulminant hepatitis in pregnancy | | **IVDU** or transfusion before 1992, chronic hepatitis and cirrhosis | **HCV** | Blood-borne, high chronicity (~80%) | | **Sexual or perinatal transmission**, DNA virus, vaccine available | **HBV** | Enveloped DNA virus, vaccine-preventable | | Chronic HBV patient with **sudden worsening** of liver function | **HDV superinfection** | HDV requires HBV; superinfection more severe | | Extrahepatic **polyarteritis nodosa** or **membranous GN** | **HBV** | Classic extrahepatic associations | | Extrahepatic **mixed cryoglobulinemia**, **MPGN**, **porphyria cutanea tarda** | **HCV** | Characteristic extrahepatic manifestations |

Common Pitfalls

• **Confusing HAV and HEV**:
• Both are **RNA, non-enveloped**, **fecal–oral**, and usually **acute**.
• **Key difference**: HEV has **high mortality in pregnancy** and is common in **Asia/Africa**.

• **Missing chronicity patterns**:
• **HAV and HEV**: generally **no chronic infection** (HEV can be chronic in immunocompromised).
• **HBV, HCV, HDV**: can be **chronic**.

• **Misinterpreting HBV serology**:
• Forgetting that **isolated anti-HBs** = **vaccination**.
• Overlooking the **window period**, where **only anti-HBc IgM** may be positive.

• **Assuming an HCV vaccine exists**:
• HCV’s **antigenic variability** prevents effective vaccine development.

• **Overlooking HDV dependence on HBV**:
• HDV **requires HBsAg**; HBV vaccination **prevents HDV**.

---

Exam Vignette with Stepwise Reasoning

**Vignette:**

A 28-year-old woman at 32 weeks’ gestation presents with 5 days of fatigue, nausea, and jaundice. She recently returned from visiting family in a rural area of South Asia where several relatives had "yellow eyes". Vital signs show mild hypotension and tachycardia. Physical exam reveals scleral icterus and right upper quadrant tenderness. Labs show markedly elevated ALT and AST. Serology for hepatitis A, B, and C is negative.

Which virus is the most likely cause of her condition?

**Stepwise reasoning:**

• **Pregnancy + acute hepatitis + high-risk region (South Asia)** → think of a virus with **fulminant hepatitis in pregnancy**.
• Transmission is likely **fecal–oral** via contaminated water.
• HAV is fecal–oral and acute, but **does not have high mortality in pregnancy**.
• HEV is a **non-enveloped RNA virus**, fecal–oral, **common in Asia**, and causes **fulminant hepatitis in pregnancy with high mortality**.

**Most likely virus: Hepatitis E virus (HEV).**

---

Key Takeaways

• **Genome and envelope:**
• **HAV, HCV, HEV**: RNA viruses; HAV and HEV are **non-enveloped**.
• **HBV**: **DNA**, enveloped, uses **reverse transcriptase**.
• **HDV**: **defective RNA virus** requiring **HBsAg**.

• **Transmission:**
• **Fecal–oral**: HAV, HEV.
• **Blood/sexual/perinatal**: HBV, HCV (primarily blood), HDV (via HBV).

• **Chronicity:**
• **Acute only**: HAV, HEV (except chronic in some immunocompromised).
• **Can be chronic**: HBV, HCV, HDV.

• **HBV serology is core Step 1 content**:
• **HBsAg** = active infection.
• **Anti-HBs** = immunity (recovery or vaccine).
• **HBeAg** = high infectivity.
• **Anti-HBc IgM** = acute infection; hallmark of **window period**.
• **Isolated anti-HBs** = **vaccination**.

• **HCV:**
• High rate of **chronic infection (~80%)**.
• **No vaccine** due to antigenic variability.
• **Direct-acting antivirals** achieve **>95% cure**.

• **HEV:**
• Fecal–oral, waterborne, **endemic in Asia/Africa**.
• **Fulminant hepatitis in pregnancy** with **high mortality**.

• **Prevention highlights:**
• **HAV**: inactivated vaccine, immune globulin post-exposure.
• **HBV**: vaccine; perinatal prophylaxis with **vaccine + HBIG**; vaccination also prevents **HDV**.
• **HEV**: sanitation and clean water; vaccine in some countries.

---

Keep Learning

To solidify hepatitis viruses for **USMLE Step 1** and **Step 2 CK**, focus on pattern recognition: genome type, envelope, transmission, and chronicity. Then layer on HBV serology interpretation, HCV diagnostic and treatment strategies, and the distinctive clinical clues like **HEV in pregnancy** and **HAV outbreaks**. Integrate these concepts into your broader understanding of liver disease and infectious disease by practicing with integrated questions and revisiting core microbiology and hepatology principles. For more structured review strategies and foundational content, explore the learning resources at **/core-concepts** and build a personalized study plan at **/build**.